[go: up one dir, main page]

GB0411145D0 - Protease inhibitors and their therapeutic applications - Google Patents

Protease inhibitors and their therapeutic applications

Info

Publication number
GB0411145D0
GB0411145D0 GBGB0411145.6A GB0411145A GB0411145D0 GB 0411145 D0 GB0411145 D0 GB 0411145D0 GB 0411145 A GB0411145 A GB 0411145A GB 0411145 D0 GB0411145 D0 GB 0411145D0
Authority
GB
United Kingdom
Prior art keywords
protease inhibitors
therapeutic applications
therapeutic
applications
protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0411145.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College Innovations Ltd filed Critical Imperial College Innovations Ltd
Priority to GBGB0411145.6A priority Critical patent/GB0411145D0/en
Publication of GB0411145D0 publication Critical patent/GB0411145D0/en
Priority to PCT/GB2005/001966 priority patent/WO2005112989A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0411145.6A 2004-05-19 2004-05-19 Protease inhibitors and their therapeutic applications Ceased GB0411145D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0411145.6A GB0411145D0 (en) 2004-05-19 2004-05-19 Protease inhibitors and their therapeutic applications
PCT/GB2005/001966 WO2005112989A1 (en) 2004-05-19 2005-05-19 Protease inhibitors and their therapeutic applications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0411145.6A GB0411145D0 (en) 2004-05-19 2004-05-19 Protease inhibitors and their therapeutic applications

Publications (1)

Publication Number Publication Date
GB0411145D0 true GB0411145D0 (en) 2004-06-23

Family

ID=32607574

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0411145.6A Ceased GB0411145D0 (en) 2004-05-19 2004-05-19 Protease inhibitors and their therapeutic applications

Country Status (2)

Country Link
GB (1) GB0411145D0 (en)
WO (1) WO2005112989A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2514878C2 (en) 2004-12-23 2014-05-10 Ксл Бехринг Гмбх Prevention of formation and/or stabilisation of thrombi
US20070248646A1 (en) * 2006-02-16 2007-10-25 Ali Hafezi-Moghadam Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage
EP2300000A1 (en) * 2008-07-03 2011-03-30 University of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
US10300119B2 (en) 2013-05-15 2019-05-28 Mor Research Applications Ltd. Compositions and methods for preventing injury during or resulting from cardiac surgery
EP3019188B1 (en) * 2013-07-08 2022-03-09 The University of Utah Research Foundation A peptide and the use thereof in the treatment of inflammatory disorders
EP3302529A4 (en) 2015-06-03 2019-02-06 The Children's Hospital Medical Center COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEONATAL BILIARY TRACT ATRÉSIA
WO2024159008A1 (en) * 2023-01-25 2024-08-02 Quoin Pharmaceuticals, Inc. Combination treatment for netherton syndrome

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58129998A (en) * 1981-11-02 1983-08-03 ジエ−ムス・ウオルタ−・リヤン Analysis of protease used in tagged proteinaceous inhibitor
ATE146970T1 (en) * 1990-10-16 1997-01-15 John Lezdey TREATMENT OF INFLAMMATION
DE19725014A1 (en) * 1997-06-13 1998-12-17 Bayer Ag Aprotinin variants with improved properties and bikunins of aprotinin variants
CA2356404C (en) * 1998-12-22 2010-03-30 Bayer Aktiengesellschaft Method for accelerating the rate of mucociliary clearance
US7704958B1 (en) * 1999-03-05 2010-04-27 Bio Holding, Inc. Methods and compositions for inhibiting apoptosis using serine protease inhibitors
AU3511500A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
EP1066834A3 (en) * 1999-07-08 2004-06-02 Thomas Dr. Stief Pharmaceutical compositions comprising a phagocyte-modulating agent
US20030007959A1 (en) * 2001-06-20 2003-01-09 John Lezdey Oral methods of treatment
US6670325B2 (en) * 2001-10-19 2003-12-30 Alpha Med Pharmaceuticals Corp. Treatment of osteocarcinoma with alpha-1—antitrypsin or secretory leucocyte protease inhibitor

Also Published As

Publication number Publication date
WO2005112989A1 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
EP1812049A4 (en) Kallikrein inhibitors and uses thereof
IL192134A0 (en) Soft protease inhibitors and pro-soft forms thereof
HK1099757A1 (en) Caspase inhibitors and uses thereof
EP1742627A4 (en) Pde4b inhibitors and uses therefor
HK1097607A1 (en) Polarizing devices and methods of making the same
IL172471A0 (en) Gsk-3 inhibitors and uses thereof
HK1087699A1 (en) Gyrase inhibitors and uses thereof
IL181670A0 (en) Substituted phenylaminothiazoles and use thereof
HK1122988A1 (en) Proteasome inhibitors and uses thereof
ZA200606176B (en) Novel Hydroxy-6-heteroarylphenanthridines and their as PDE4 inhibitors
ZA200509700B (en) Caspase inhibitors and uses thereof
IL179497A0 (en) Carboranylporphyrins and uses thereof
HK1136819A1 (en) Novel dithiolopyrrolones and their therapeutic applications
EP1922086A4 (en) Targeted protein kinase c inhibitors and uses thereof
HK1103645A1 (en) New pharmaceutical uses of the lipase inhibitor
IL177435A0 (en) Expression of plasminogen and microplasminogen in duckweed
EP1841419A4 (en) Cathepsin k inhibitors and obesity
IL181819A0 (en) Enzyme inhibitors and uses thereof
EP1663279A4 (en) Modified protease inhibitors
IL180365A0 (en) Carboranylporphyrins and uses thereof
EP1704142A4 (en) Protease inhibitors
EP1883404A4 (en) P38 inhibitors and methods of use thereof
GB0402007D0 (en) Acoustic devices and fluid-gauging
GB0516069D0 (en) Pharmaceutical and use thereof
EP1838288A4 (en) Therapeutic materials and methods

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)